Iscalimab, a fully human, pathway-blocking anti-CD40 monoclonal antibody that has been modified with a N297A mutation to render it unable to mediate Fcγ-dependent effector functions, can blockade the CD40−CD40L pathway, inhibiting SS-related pathology [66,67]. This evidence concerns the gene CD40 and synovial sarcoma.